Ocular Therapeutix OCUL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ocular Therapeutix’s reported figures.
Based on trailing twelve months.
The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ocular Therapeutix's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ocular Therapeutix's EBITDA margin?
- Ocular Therapeutix (OCUL) reported EBITDA margin of -566.5% in Q1 2026.
- How has Ocular Therapeutix's EBITDA margin changed year-over-year?
- Ocular Therapeutix's EBITDA margin decreased by 68.8% year-over-year, from -335.7% to -566.5%.
- What is the long-term trend for Ocular Therapeutix's EBITDA margin?
- Over 5 years (2020 to 2025), Ocular Therapeutix's EBITDA margin has grown at a 8.2% compound annual growth rate (CAGR), from -345.2% to -511.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.